Other

Botulinum Toxin Research Associates, Inc.

Revance Therapeutics, Inc.

Martin Andrew Acquadro

Gary E Borodic

Clark Berg Foster

Ciaran Bolger

Michael Baltay

Bruce A Rasmussen

Yahya Shehabi

An eye sensor, system and method for measuring fixational eye movements of an individual's eyeball (e.g., ocular microtremors and microsaccades) to provide a variable voltage biosignal for measuring the individual's brainstem activity is provided. The eye sensor comprises a sensor mounted on the individual's closed or opened eyelid so as to be deflected by the fixational eye movements of the eyeball. A shielded flexible ribbon assembly supplies the biosignal generated by the sensor to an amplifier located on the individual's skin where the biosignal is amplified. The amplifier is interconnected with a signal processor and a display by which graphical and numerical representations of the biosignal are made accessible to an anesthesiologist, intensivist or clinician. A method for analyzing the biosignal to determine the brainstem activity of a patient is also provided.

Method of measuring sedation using ocular microtremor (OMT) and microsaccades (MS)

An eye sensor, system and method for measuring fixational eye movements of an individual's eyeball (e.g., ocular microtremors and microsaccades) to provide a variable voltage biosignal for measuring the individual's brain stem activity. The eye sensor comprises a sensor mounted on the individual's closed or opened eyelid so as to be deflected by the fixational eye movements of the eyeball. A shielded flexible ribbon assembly supplies the biosignal generated by the sensor to an amplifier located on the individual's skin where the biosignal is amplified. The amplifier is interconnected with a signal processor and a display by which graphical and numerical representations of the biosignal are made accessible to an anesthesiologist, intensivist or clinician. A method for analyzing the biosignal to determine the brainstem activity of a patient.

Ocular micro tremor (OMT) sensor, system and method

Methods of using botulinum toxin based pharmaceuticals are disclosed. The methods cause vasodilatation and decreased flow resistance of certain vascular beds for the purpose of increasing blood flow to a region in order to positively impact deterioration from a number of diseases.

Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds

An ocular micro tremor (OMT) sensor, system and method for measuring micromovements of an individual's eyeball having an amplitude of 40 micrometers or less to provide a variable voltage biosignal for measuring the individual's brain stem activity. The OMT sensor includes a flexible piezo-active sensing element mounted at the individual's closed or opened eyelid so as to be deflected by the micromovements of the eyeball. A shielded flexible ribbon assembly supplies the biosignal generated by the piezo-active sensing element to an OMT amplifier located on the individual's skin where the biosignal is amplified. The OMT amplifier is interconnected with a signal processor and a display by which graphical and numerical representations of the biosignal are made accessible to an anesthesiologist, intensivist or clinician.

The present invention provides methods for treating sinus-evoked headaches using botulinum toxin injected or applied in multiple subcutaneous locations over divisions of the trigeminal nerve in soft tissues and dermatomes overlying the corresponding effected sinuses implicated in the etiology of the pain.

Treatment of sinusitis related chronic facial pain and headache with botulinum toxin injections

Devices, methods and kits are disclosed for preparing and administering less-painful formulations oftoxin. The devices, methods and kits of the present invention are comprised of or use an acidic formulation oftoxin, or, in certain embodiments, a freeze- or flash-dried composition oftoxin, having a long shelf-life which is subsequently mixed with an acid-neutralizing solution and, optionally a sequestration agent prior to administration to a patient in need thereof. The pH-neutralized formulation oftoxin is pharmaceutically acceptable for administration to a patient and is significantly less painful than acidic formulations oftoxin or formulations oftoxin having unnecessary antigens.

Growing community of inventors

Wellesly, MA, United States of America

Martin Andrew Acquadro